QPEX BIOPHARMA, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2018-10-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.qpexbio.com
Clinical Trials
10
Active:1
Completed:6
Trial Phases
2 Phases
Phase 1:8
Not Applicable:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Phase 1
8 (80.0%)Not Applicable
2 (20.0%)A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
Not Applicable
Not yet recruiting
- Conditions
- Bacterial Infections
- Interventions
- Drug: Cefiderocol/Xeruborbactam
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Qpex Biopharma, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT07104162
- Locations
- 🇺🇸
University of Miami Clinical Pharmacology, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Mass Balance Study of [14C]Xeruborbactam (QPX7728) in Healthy Adult Male Participants
Not Applicable
Active, not recruiting
- Conditions
- ADME
- Interventions
- Drug: [14C]Xeruborbactam
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Qpex Biopharma, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT07083817
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
🇬🇧Quotient Sciences, Nottingham, United Kingdom
A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult Participants
Phase 1
Recruiting
- Conditions
- Bacterial Infections
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-08-11
- Lead Sponsor
- Qpex Biopharma, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06547554
- Locations
- 🇺🇸
Minneapolis Clinic, Minneapolis, Minnesota, United States
PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment
Phase 1
Completed
- Conditions
- Bacterial Infections
- Interventions
- Drug: Xeruborbactam Oral Prodrug
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Qpex Biopharma, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06157242
- Locations
- 🇺🇸
University of Miami Clinical Pharmacology, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants
Phase 1
Recruiting
- Conditions
- Bacterial Infections
- Interventions
- Drug: Xeruborbactam Oral ProdrugDrug: Xeruborbactam Oral Prodrug Placebo
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Qpex Biopharma, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT06079775
- Locations
- 🇦🇺
CMAX, Adelaide, South Australia, Australia
- Prev
- 1
- 2
- Next
News
No news found